Childhood cancers trials in Hungary
34 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.
- Phase 4Taking peopleDabrafenib and/or Trametinib Rollover Study
- Where
- Budapest XII, Debrecen
- Age
- 18 years to 100 years
- People
- 100 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT03340506 · EU 2023-509318-13-00 - Phase 2Taking peopleBelzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
- Where
- Budapest
- Age
- 12 years and over
- People
- 355 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT04924075 · EU 2023-504853-11-00 - Phase 2Taking peopleStudy to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
- Where
- Debrecen
- Age
- 1 year to 18 years
- People
- 50 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07354074 - Phase 4Taking peopleAsciminib Roll-over Study
- Where
- Budapest VIII, Eger
- Age
- 7 years to 100 years
- People
- 347 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT04877522 · EU 2023-507557-16-00 - Phase 1/2Taking peopleA Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
- Where
- Budapest
- Age
- 6 months to 30 years
- People
- 65 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT05533775 - Phase 1/2Taking peopleA Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Glofitamab in Monotherapy and in Combination with Chemoimmunotherapy in Pediatric and Young Adult Participants with Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
- Where
- Budapest
- Age
- Up to 17 years
- People
- 37 worldwide
- Run by
- F. Hoffmann-La Roche AG
See details and how to join2023-504264-41-00 · EU 2023-504264-41-00 - Phase 2/3Taking peopleLong-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
- Where
- Budapest IX, Debrecen
- People
- 1,541 worldwide
- Run by
- Celgene
See details and how to joinNCT03435796 · EU 2023-504201-36-00 - Phase 1/2Taking peopleSubstudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Where
- Budapest
- Age
- 6 months to 25 years
- People
- 90 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06395103 · EU 2023-507178-41-00 - Phase 1/2Taking peopleA Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
- Where
- Budapest
- Age
- 1 month to 17 years
- People
- 134 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07630974 · EU 2025-522339-32-00 - Phase 3Taking peopleInternational Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)
- Where
- Budapest
- Age
- 1 year to 64 years
- People
- 750 worldwide
- Run by
- Charite University, Berlin, Germany
See details and how to joinNCT07476729 · EU 2023-509392-17-00 - Phase 3Taking peopleStudy of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
- Where
- Budapest VIII, Debrecen, Győr, Szekszárd
- Age
- 12 years and over
- People
- 468 worldwide
- Run by
- Syndax Pharmaceuticals
See details and how to joinNCT07211958 · EU 2025-522279-27-00 - Phase 3Taking peopleInternational Euro Ewing (iEuroEwing) trial for treatment optimisation in patients with Ewing sarcoma
- Where
- Budapest, Budapest IX, Budapest VIII, Debrecen, Miskolc, Pécs, Szeged
- Age
- Up to 64 years
- People
- 1,351 worldwide
- Run by
- GPOH gGmbH
See details and how to join2022-501180-40-00 · EU 2022-501180-40-00 - Phase 3Taking peopleInterfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia
- Where
- Budapest, Pécs
- Age
- 1 day to 1 year
- People
- 160 worldwide
- Run by
- Princess Maxima Center for Pediatric Oncology
See details and how to joinNCT05327894 · EU 2022-502503-30-00 - Phase 2/3Taking peopleSafety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
- Where
- Budapest XII, Pécs
- Age
- 18 years and over
- People
- 740 worldwide
- Run by
- Eikon Therapeutics
See details and how to joinNCT06697301 · EU 2024-512659-19-00 - Phase 1/2Taking peopleA Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
- Where
- Budapest
- Age
- 1 month to 17 years
- People
- 50 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06941272 · EU 2024-518771-66-00 - Phase 2Taking peopleA Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
- Where
- Budapest, Miskolc, Pécsi Tudományegyetem Klinikai Központ
- Age
- 1 year to 17 years
- People
- 100 worldwide
- Run by
- Pfizer
See details and how to joinNCT05748171 · EU 2023-509810-13-00 - Phase 3Taking peopleAn international trial for children with atypical teratoid/rhabdoid tumours (ATRT)
- Where
- Budapest, Budapest IX, Pécs
- Age
- Up to 17 years
- People
- 301 worldwide
- Run by
- GPOH gGmbH
See details and how to join2022-501456-28-00 · EU 2022-501456-28-00 - Phase 3Taking peopleStudy to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
- Where
- Budapest VIII, Szeged
- Age
- 12 years to 100 years
- People
- 240 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06784752 · EU 2024-518325-15-00 - Phase 3Taking peopleSIOP RANDOMET 2017
- Where
- Budapest, Pécs
- Age
- Up to 17 years
- People
- 409 worldwide
- Run by
- GPOH gGmbH
See details and how to join2023-508926-91-00 · EU 2023-508926-91-00 - Phase 2/3Taking peopleAllogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
- Where
- Budapest
- Age
- 1 month to 18 years
- People
- 1,800 worldwide
- Run by
- St. Anna Kinderkrebsforschung
See details and how to joinNCT01949129 · EU 2024-512657-24-00 - Phase 2Taking peopleStudy to evaluate the safety and efficacy of asciminib in pediatric participants with chronic myeloid leukemia.
- Where
- Debrecen
- Age
- Up to 17 years
- People
- 16 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2025-522138-29-00 · EU 2025-522138-29-00 - No phaseTaking peopleCerebellar Mutism Syndrome Study
- Where
- Budapest
- Age
- Up to 18 years
- People
- 2,000 worldwide
- Run by
- Copenhagen University Hospital, Rigshospitalet
See details and how to joinNCT02300766 - Phase 1Taking peopleA Study to Assess Adverse Events and How Pivekimab Sunirine Moves Through the Body of Pediatric Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Where
- Budapest
- Age
- Up to 17 years
- People
- 18 worldwide
- Run by
- AbbVie Deutschland GmbH & Co. KG
See details and how to join2024-520125-36-00 · EU 2024-520125-36-00 - Phase 1/2Taking peopleA Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- Where
- Budapest VIII, Budapest XII
- Age
- 12 years and over
- People
- 500 worldwide
- Run by
- Turning Point Therapeutics, Inc.
See details and how to joinNCT03093116 · EU 2024-512606-25-00 - Phase 3Taking peopleStudy on chemotherapy and experimental drugs in patients with Philadelphia Chromosome positive and ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia
- Where
- Budapest, Budapest VIII, Debrecen, Pécs, Szeged
- Age
- Up to 64 years
- People
- 87 worldwide
- Run by
- Universita Degli Studi Di Milano Bicocca
See details and how to join2025-520982-39-00 · EU 2025-520982-39-00